Almirall: Almirall, S.A. Announces Chief Financial Officer Changes

Almirall, S.A. announced the appointment of Jon U. Garay Alonso as Chief Financial Officer as of August 2025, succeeding Mike McClellan, who will leave the company in September 2025, after nearly six successful years as CFO. This planned transition is focused on maintaining business continuity and enabling the organization to keep and further build its strong trajectory towards achieving its ambition as European leader in medical dermatology. Jon U. Garay Alonso is currently CFO at Camurus, a science-led, global pharmaceutical company focused on developing and commercializing innovative medicines with the potential to significantly improve treatment for patients with severe and chronic diseases within Central Nervous System (CNS) diseases, rare diseases, endocrine disorders, oncology and supportive care. Jon previously held positions with increasing seniority at Baxter, Gambro, Convatec, and Bristol Myers Squibb after having worked in different industry sectors before. Jon has bachelor?s and master?s degrees in business administration and has continued his professional education throughout his career. Jon will relocate from Lund, Sweden to Barcelona and report to Carlos Gallardo, Almirall Chairman and CEO. Almirall, S.A. announced the appointment of Jon U. Garay Alonso as Chief Financial Officer as of August 2025, succeeding Mike McClellan, who will leave the company in September 2025, after nearly six successful years as CFO. This planned transition is focused on maintaining business continuity and enabling the organization to keep and further build its strong trajectory towards achieving its ambition as European leader in medical dermatology. Jon U. Garay Alonso is currently CFO at Camurus, a science-led, global pharmaceutical company focused on developing and commercializing innovative medicines with the potential to significantly improve treatment for patients with severe and chronic diseases within Central Nervous System (CNS) diseases, rare diseases, endocrine disorders, oncology and supportive care. Jon previously held positions with increasing seniority at Baxter, Gambro, Convatec, and Bristol Myers Squibb after having worked in different industry sectors before. Jon has bachelor?s and master?s degrees in business administration and has continued his professional education throughout his career. Jon will relocate from Lund, Sweden to Barcelona and report to Carlos Gallardo, Almirall Chairman and CEO.